Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety,
pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of
patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma
IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of
NEO212 when given with select SOC for the treatment of solid tumor patients with
radiographically confirmed uncontrolled brain metastasis. The study will have three phases,
Phase 1, Phase 2a and Phase 2b.